St John’s wort has something many supplements lack: clinical evidence of benefit for some people with depression. It also has a substantial capacity to interfere with medicines. Those findings belong in the same sentence. For anyone considering a herbal product for mood, the question is whether the particular preparation, the evidence, and the person’s other treatments can safely be considered together.
What the short-term trials actually support
The NIH’s National Center for Complementary and Integrative Health evidence summary, updated in May 2025 describes St John’s wort as appearing more effective than placebo and as effective as standard antidepressants for mild or moderate depression. It also identifies uncertainty about severe depression and treatment lasting longer than twelve weeks. This is a summary of clinical evidence, rather than a new head-to-head trial or a guarantee of benefit.
That is a meaningful clinical signal. It is also a bounded one. A comparison over several weeks does not answer whether benefit persists over years, whether relapse becomes less likely, or whether a different extract produces the same result. Comparable average results in these trials do not establish that two treatments are interchangeable for an individual.
The NIH’s National Center for Complementary and Integrative Health summary likewise describes possible benefit for mild or moderate depression, with uncertainty about severe illness and treatment beyond twelve weeks. This is evidence about treating a defined condition, not evidence that otherwise well adults should take a daily mood supplement. It does not establish a benefit for longevity.
The extract matters more than the plant name
St John’s wort is also called Hypericum perforatum, as identified in the NIH overview. The preparation matters: an extract used in research is a particular product, rather than a promise about everything sold under the plant’s name. Its formulation and composition belong alongside the outcome when evaluating a claim.
For an evidence claim, the useful questions are specific. Was the research conducted on an extract or a tea? What was the daily amount of that preparation? Was its composition characterised? Is the manufacturer pointing to evidence for its own formulation, or borrowing the reputation of the ingredient? These questions are part of evaluating a claimed treatment, rather than an invitation to select a product independently.
The NHS explanation of depression treatment highlights variation in active ingredients between brands and batches. That makes it difficult to predict an individual product’s effects. An impressive trial cannot close that gap by itself. Nor does a larger number of milligrams resolve it: the amount of a preparation is not a complete description of what is in it.
Why there is no universal dose to copy
A concrete example comes from Nobakht and colleagues’ 2022 review in the Iranian Journal of Basic Medical Sciences. Its table of clinical studies describes the historical 2005 Szegedi trial: 251 adults received the extract WS 5570 or paroxetine for six weeks. The extract arm began at 900 mg daily, with an increase to 1,800 mg for initial non-responders. The review describes WS 5570 as a methanol extract containing 3–6% hyperforin and 0.1–0.3% hypericin. This reports a supervised trial preparation and protocol; it is not a starting-dose recommendation and cannot be transferred to arbitrary retail products.
Readers understandably want a number. Here, presenting a single daily dose would imply a consistency that the evidence and products do not provide. NICE’s adult depression guideline, recommendation 1.4.38, acknowledges possible benefit in less severe depression but advises healthcare professionals against prescribing or advising its use. Its reasons include uncertain appropriate doses, uncertain persistence of effect, variation between preparations, and potentially serious interactions.
That recommendation sits within the current NG222 guideline, published in 2022; the St John’s wort recommendation itself is retained from 2009. It should not be described as a new trial result. It is a clinical judgement that weighs more than whether a symptom score improved in an experiment.
Our editorial conclusion follows that distinction. This article does not offer a starting dose, a titration schedule, or a way to substitute the herb for prescribed treatment. Before a dose could be discussed responsibly, the preparation and the clinical context would have to be clear. The absence of a dosing tip is a consequence of the uncertainty.
Interactions can undermine essential treatment
The NIH summary warns that St John’s wort can weaken the effects of medicines including hormonal contraceptive pills, warfarin, some seizure medicines, transplant medicines, some cancer treatments, and certain HIV medicines. It can also cause serious serotonin-related effects when combined with some antidepressants or other medicines affecting serotonin. The interaction list is extensive; it is not limited to psychiatric treatment.
That makes the entire medicine list relevant, including something taken for a condition unrelated to mood. A product does not need to cause an obvious immediate side effect to create a problem: reducing the effectiveness of another treatment can be the harm. A pharmacist needs the actual product details alongside the medicines, rather than only the reassurance that it is herbal.
The NIH cautions that interactions can weaken life-saving medicines or cause dangerous side effects. Someone already taking St John’s wort with prescribed treatment needs professional advice about managing the combination. This is not a reason to stop an antidepressant, anticoagulant, or other essential medicine independently, or to plan a switch using an online timetable.
Tolerability is not the whole safety assessment
Short-term tolerability does not settle the safety question. The NIH summary treats adverse effects and medicine interactions as distinct concerns. A person may tolerate the preparation while another medicine becomes less effective. Any reassuring account of ordinary side effects therefore needs to sit alongside the interaction warning, rather than displace it.
The NIH safety summary lists diarrhoea, dizziness, trouble sleeping, restlessness, and potentially severe skin reactions after sun exposure. It warns that use during pregnancy may be unsafe and that exposed breastfeeding infants can experience colic, drowsiness, and lethargy. A person who is pregnant, breastfeeding, or considering pregnancy needs advice about appropriate depression care rather than an assumption that a plant preparation is the gentler option.
The NIH’s detailed depression information reports cases of worsening psychotic symptoms in people with bipolar disorder or schizophrenia. It also describes potentially life-threatening serotonin effects with certain antidepressant combinations, including agitation, diarrhoea, rapid heartbeat, hallucinations, and raised temperature. Severe agitation, fever, or confusion after combining products warrants urgent medical assessment. A safety paragraph cannot replace an interaction check.
A mood concern deserves assessment, not a shopping decision
Depression is more than the question of which substance might improve a symptom score. The NHS account of depression treatment describes psychological treatments, medicines, and other approaches considered according to the person’s needs. That is a care framework, rather than a choice between two bottles. A treatment decision needs to account for the person as well as the proposed product.
For the reader, this changes the first conversation. Rather than asking which bottle resembles an antidepressant, it is more useful to describe how long things have been difficult, how sleep and daily activities have changed, and what treatments or substances are already involved. An assessment can address the problem that prompted the search.
If someone is at immediate risk of harming themselves or cannot keep themselves safe, emergency help is needed: in the UK, NHS emergency guidance says to call 999 or go to A&E. The NHS depression treatment page provides the route into established care. Choosing a supplement should not delay that care.
What this means in practice
- Bring the packet, or clear photographs of its ingredients and stated amounts, to a pharmacist or GP if St John’s wort is being considered or is already in use.
- Include every medicine and supplement in that discussion, particularly contraceptives, antidepressants, anticoagulants, and seizure treatments.
- Ask whether the evidence cited concerns the actual preparation and a population comparable to the person who would take it.
- Discuss persistent low mood and its effect on everyday life with a healthcare professional; do not use a product trial as a substitute for assessment.
- Seek professional advice about any proposed combination or switch. Keep changes to prescribed treatment within the agreed care plan.
What we don’t know
The major gaps concern longer-term benefit, severe depression, and how reliably results transfer between preparations. A favourable short-term average does not identify who will benefit or who will encounter an interaction. No claim about longer life follows from the symptom trials discussed here. The evidence supports taking the herb seriously as a biologically active preparation; it does not support treating retail availability as clinical clearance.
St John’s wort deserves the same questions as any proposed treatment: what is the product, what benefit is demonstrated, and what could it disrupt?
Photo: Samar L. on Pexels. Hypericum flowers, used as a botanical illustration rather than a guide to identifying or preparing medicinal plants.
